CURX Curanex Pharmaceuticals Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 2025942 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-850.0%
TTM EPS YoY-509.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-146.5%
ROA-140.3%
ROIC (approx.)-207.7%
Asset turnover—
Leverage & solvency
Liabilities / assets17.8%
Debt / equity0.00x
Current ratio17.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.34x
Accruals ratio-91.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.95M | $2.59M | $2.26M | $2.31M | $677,474 | — | — | — |
| SG&A expense | $877,121 | $731,843 | $927,197 | $786,340 | $273,853 | $57,658 | $137,452 | $72,690 |
| Operating income | -$2.83M | -$3.33M | -$3.18M | -$3.09M | -$951,327 | -$57,658 | -$137,452 | -$147,366 |
| Interest expense | — | — | — | $0 | $4,090 | $3,091 | $1,356 | — |
| Net income | -$2.82M | -$3.29M | -$3.15M | -$3.07M | -$954,059 | -$60,346 | -$137,583 | -$145,939 |
| EPS (basic) | -1.86 | -0.12 | -0.11 | — | -0.75 | 0.00 | -0.01 | — |
| EPS (diluted) | -1.86 | -0.12 | -0.11 | — | -0.75 | 0.00 | -0.01 | — |
| Weighted avg. shares (diluted) | 1.52M | 28.36M | 28.34M | — | 1.28M | 24.00M | 24.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.58M | $2.94M | $4.00M | $4.97M | $5.80M | $108,862 | — | $148,891 |
| Current assets | $2.56M | $4.79M | $8.09M | $11.23M | $14.42M | $711,337 | — | $517,935 |
| Total assets | $3.10M | $5.07M | $8.41M | $11.58M | $14.48M | $787,174 | — | $517,935 |
| Current liabilities | $143,300 | $104,306 | $128,734 | $137,030 | $185,955 | $75,927 | — | $14,575 |
| Total liabilities | $551,831 | $286,254 | $332,644 | $361,040 | $185,955 | $481,743 | — | $14,575 |
| Shareholders' equity | $2.55M | $4.79M | $8.08M | $11.22M | $14.29M | $305,431 | $365,777 | $503,360 |
| Shares outstanding | 1.57M | 28.36M | 28.36M | 1.42M | 28.34M | 24.00M | — | 1.20M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.36M | -$1.08M | -$954,560 | -$857,404 | -$9.19M | -$290,081 | -$149,948 | -$95,427 |
| Financing cash flow | — | — | — | $0 | $14.91M | $200,000 | $200,000 | $0 |
| Stock-based compensation | $154,009 | $0 | $9,792 | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.